Press Releases Femasys Inc.

Equities

FEMY

US31447E1055

Market Closed - Nasdaq Other stock markets 01:30:00 28/06/2024 am IST			5-day change	1st Jan Change
1.15 ^USD	+10.58%		-9.45%	+17.95%

20/06	Femasys Secures CE Mark Approvals for Four Women's Health Products; Shares Up Over 14%	MT
09/05	Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam	27/06	GL
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe	20/06	GL
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative	20/05	AQ
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative	17/05	GL
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council	16/05	GL
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update	09/05	GL
Femasys Expands Commercial Management Team with Addition of Experienced New Hires	07/05	GL
Femasys Expands Commercial Management Team with Addition of Experienced New Hires	07/05	AQ
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives	19/04	AQ
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives	18/04	GL
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update	29/03	GL
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update	29/03	AQ
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility	21/03	AQ
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape	21/03	GL
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility	20/03	GL
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility	20/03	AQ
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024	13/03	GL
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution	06/03	GL
Femasys FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF	29/02	AQ
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF	28/02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Femasys Inc.

Equities

FEMY

US31447E1055

Press Releases

Filters